Navigation Links
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
Date:10/14/2010

SEATTLE, Oct. 14 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute (NYSPI). In Omeros' Addiction program, the Company is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARgamma) agonists for the prevention and treatment of addiction to substances of abuse, such as opioids, nicotine and alcohol, as well as other compulsive behaviors, including eating disorders. Data from earlier European pilot clinical studies and animal models of addiction have demonstrated a previously unknown link between PPARgamma and addiction disorders.

Earlier this year, Omeros announced that NIDA agreed to fund substantially all of the costs of a Phase 2 clinical study to be conducted by NYSPI researchers to evaluate a PPARgamma agonist for the treatment of addiction to prescription opioids. The NIDA support announced today will be used to fund additional Phase 2 clinical studies to evaluate the effect of a PPARgamma agonist in combination with other agents on the use of heroin and cigarettes.  These clinical studies will also be conducted at the NYSPI and will be led by the recipients of this grant award, Dr. Sandra D. Comer and Dr. Adam Bisaga. Omeros will have the right to reference the data obtained from these studies for subsequent submissions to the FDA and will retain all other rights in connection with its Addiction program.

"This latest grant from NIDA underscores the potential of our Addiction program to yield a
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros Secures $40 Million Committed Equity Financing Facility
2. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
3. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
4. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
5. Omeros Commences Initial Public Offering of Common Stock
6. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
10. Omeros and BlueCrest Announce $20 Million Debt Facility
11. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Ceres, Inc. (Nasdaq: ... a U.S. patent for a genetic sequence derived from ... as research, product development and plant transformation. The company ... biosynthetic processes that are the target of a class ... companies a commercial license to the innovation, including an ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/27/2015)... 27, 2015 ­ Caris Life Sciences®, a ... precision medicine, today announced it has appointed the Levine ... of excellence site in the Caris Centers of Excellence ... Cancer Institute is one of the largest cancer care ... new cancer patients annually. Derek Raghavan , M.D., ...
(Date:5/26/2015)... Regenestem Network has announced the grand ... Aires, Argentina. The clinic will be lead by Silvina ... assembled a multidisciplinary team of medical professionals who specialize ... Madero office. , The new Regenestem Network members ... studies in cellular therapies, and establish Regenestem protocols to ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
... January 28 The Binding Site Limited,("The Binding ... company, today announces the publication of the first,international ... and management of multiple myeloma, a cancer of ... disorders. , The guidelines ...
... an announcement made recently by Astellas Pharma Inc., CV Therapeutics, ... received a letter dated November 13, 2008 from Astellas setting ... at a price of $16.00 per share, subject to due ... deliberation, with the assistance of its financial and legal advisors, ...
... PTS by Albemarle responds to the demand in ... 27 Leading specialty chemical company, Albemarle Corporation, ... company, Zymes LLC, have joined forces to scale-up ... The next generation technology promotes the clear ...
Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... Bell, PA (January 7, 2013) The PATH Malaria ... MKT: INO) today announced a follow-on collaboration to ... technologies. Researchers will test whether a novel vaccine ... innovative vaccine delivery technology called electroporation could induce ...
... Researchers have identified four new regions on the human ... dangerous condition found predominantly in people with ancestors along ... this 4,000-mile network linking the Far East with Europe ... the Silk Road disease, genes. National Institutes of Health ...
... BOSTON January 8, 2013 -- As part of their ... development of obesity, Joslin Diabetes Center scientists have identified a ... major role in energy metabolism and fat storage. This ... obesity. The study is being published today ahead of print ...
Cached Biology News:MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech 2MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech 3Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 2Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 3Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 4Joslin researchers identify important factor in fat storage and energy metabolism 2